• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Boston Scientific CEO Mike Mahoney talks Lotus decision, post-COVID outlook

Boston Scientific CEO Mike Mahoney talks Lotus decision, post-COVID outlook

December 1, 2020 By Sean Whooley

Boston ScientificBoston Scientific (NYSE:BSX) made waves this month when it recalled and retired its Lotus TAVR product line.

Subsequent layoffs, first in Minnesota, then in Ireland, highlighted the impact of the decision to pull Lotus from the highly competitive market as a result of complexities related to the product delivery system and solely that — as the valve has achieved positive and clinically effective performance post-implant.

Speaking in a Q&A with analyst Vijay Kumar as part of the Evercore ISI 2020 HealthCONx Conference, Boston Scientific chairman & CEO Mike Mahoney explained the tough call the company had to make by taking Lotus off the market.

“We’re clearly disappointed by the news, but we make difficult choices in our portfolio to maximize shareholder value,” Mahoney said. “We wanted to be very objective about our current position with Lotus and more importantly what we saw as the future of the next two to three years.

“Essentially, the cost to invest to further advance the Lotus device and its delivery system, plus the timeline to do that and make it more of a workhorse valve, wasn’t feasible compared to other options we had.”

The company’s VP of investor relations, Susie Lisa, added that there was anxiety in approaching physicians with the Lotus news, “but while there was disappointment, there was also understanding.”

Mahoney said the company’s focus is now shifting to its Acurate neo2 transcatheter aortic valve implantation (TAVI) system, which is in the midst of a controlled launch in Europe, having received CE Mark approval in April.

Acurate neo2 has expanded indication for patients with aortic stenosis (with no specified age or risk level) who are considered appropriate candidates for the treatment by their heart team. The system restores function and normal blood flow through a severely narrowed aortic valve and includes new annular sealing technology for conforming to irregular, calcified anatomies.

The system’s annular sealing technology also minimizes paravalvular regurgitation or leaking (PVL) and offers access to smaller and more complex vessels at the entry site, allowing for accurate valve positioning while the top-down deployment mechanism further supports stable placement and release.

“We think Acurate neo2 is a different category of valve from Lotus and the customers who like Acurate are really enjoying [the next-generation] neo2,” Mahoney said. “One of the benefits [of retiring Lotus] will be that it will allow us to focus on this platform.”

Kumar questioned if the retiring of Lotus and the increased focus on Acurate neo2 could create cannibalization in the market, but Mahoney was assured that wasn’t the case.

“Both valves have different characteristics and are often used in different patients,” Mahoney said. “We don’t think the removal of Lotus will cannibalize Acurate neo2.”

Watchman optimism

Mahoney offered a positive outlook for the company’s Watchman FLX heart implant for left atrial appendage occlusion via ablation for non-valvular atrial fibrillation (Afib).

“Watchman FLX has exceeded all of our expectations with the growth and adoption of that platform,” Mahoney said. “We’ve seen quarter-over-quarter improvement in the Watchman business with very fast adoption since the launch.”

Boston Scientific’s chairman & CEO highlighted ease of use and enhanced safety profiles as reasons for quick adoption, with expansion evident in locations such as China and Japan. The company was impressed with the product’s growth despite the impact of the pandemic, too.

“We don’t see any change to the momentum that Watchman continues to generate,” Mahoney said.

COVID-19-related outlook

While Boston Scientific, like most companies, is not going to provide 2021 guidance, with the impact of COVID-19 still looming large, Mahoney expressed optimism regarding the company’s future.

Mahoney noted that, within the culture of the company, the pandemic has changed very little in terms of focus on innovation and excitement over future progress.

“We’ve seen the business start to improve significantly, but still not at a normal basis given the impact of COVID,” Mahoney said. “It’s been a challenging year. As we look forward to 2021 and a post-COVID environment, our view as a company hasn’t changed. … We’re supported by a terrific portfolio and a strong balance sheet.”

The chairman & CEO added that the regulatory pathway has been strong during the pandemic and, despite it being something of a “lost year financially,” the company’s innovation cycle hasn’t slowed.

“We think the company post-COVID will be stronger than the company we had pre-COVID,” Mahoney said.

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, MassDevice Earnings Roundup, Replacement Heart Valves, Research & Development, Structural Heart, Wall Street Beat Tagged With: Boston Scientific, coronavirus, COVID-19, tavr

In case you missed it

  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

RSS From Medical Design & Outsourcing

  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS